Literature DB >> 35763108

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.

Sofya Marchenko1, Iris Piwonski1, Inga Hoffmann1, Bruno Valentin Sinn1, Catarina Alisa Kunze1, Nanna Monjé1, Jonathan Pohl1, Hagen Kulbe2,3, Wolfgang Daniel Schmitt1, Sylvia Darb-Esfahani4, Elena Ioana Braicu2,3, Ann-Christin von Brünneck1, Jalid Sehouli2,3, Carsten Denkert5, David Horst1, Korinna Jöhrens6, Eliane Tabea Taube7.   

Abstract

PURPOSE: In recent years the tumor microenvironment and its interaction with the tumor has emerged into research focus with increased attention to the composition of Tumor-infiltrating lymphocytes. We wanted to quantify the composition of Regulatory T cells (Tregs) and T helper 17 cells (Th17 cells) and their prognostic impact in high-grade serous tubo-ovarian carcinoma.
METHODS: Tregs and Th17 cells were determined by immunohistochemical analysis of CD25 FoxP3 and RORγt, respectively on tissue microarrays of a cohort of 222 patients with reviewed histology and available clinical data. Expression was analyzed with Qupath for quantification and integration with clinical data enabled calculation of prognostic impact. For validation FOXP3 and RORC mRNA expression levels from 502 patients with HGSC in publicly available datasets were evaluated.
RESULTS: An average percentage of 0.93 Tregs and of 0.06 Th17 cells was detected per cells in overall tissue. Optimal cut-offs were determined and higher Tregs were associated with a better overall survival in stroma (p = 0.006), tumor area (p = 0.0012) and overall tissue (p = 0.02). After accounting for well-known prognostic factors age at diagnosis, residual tumor and FIGO stage, this association remained significant for stromal Tregs with overall survival (p = 0.02). Survival analysis for Th17 cells revealed no significant association with survival rates. Moreover, lower Th17/Treg ratios had a positive impact on patient overall survival (p = 0.025 tumor, p = 0.049 stroma and p = 0.016 overall tissue).
CONCLUSION: Our results outline a positive prognostic effect for higher Tregs but not for Th17 in high grade serous tubo-ovarian carcinoma.
© 2022. The Author(s).

Entities:  

Keywords:  Digital pathology; High grade ovarian carcinoma; Prognosis; Regulatory T-cells; Tumor microenvironment; Tumor-infiltrating lymphocytes

Year:  2022        PMID: 35763108     DOI: 10.1007/s00432-022-04101-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.

Authors:  Sara Corvigno; Jared K Burks; Wei Hu; Yanping Zhong; Nicholas B Jennings; Nicole D Fleming; Shannon N Westin; Bryan Fellman; Jinsong Liu; Anil K Sood
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-02       Impact factor: 4.322

2.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

3.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

4.  Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.

Authors:  Anna Fialová; Simona Partlová; Luděk Sojka; Hana Hromádková; Tomáš Brtnický; Jitka Fučíková; Petr Kocián; Lukáš Rob; Jiřina Bartůňková; Radek Spíšek
Journal:  Int J Cancer       Date:  2012-08-24       Impact factor: 7.396

5.  A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

Authors:  F Farace; C Massard; N Vimond; F Drusch; N Jacques; F Billiot; A Laplanche; A Chauchereau; L Lacroix; D Planchard; S Le Moulec; F André; K Fizazi; J C Soria; P Vielh
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

6.  Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.

Authors:  J Stuart Ferriss; Youngchul Kim; Linda Duska; Michael Birrer; Douglas A Levine; Christopher Moskaluk; Dan Theodorescu; Jae K Lee
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

7.  QuPath: Open source software for digital pathology image analysis.

Authors:  Peter Bankhead; Maurice B Loughrey; José A Fernández; Yvonne Dombrowski; Darragh G McArt; Philip D Dunne; Stephen McQuaid; Ronan T Gray; Liam J Murray; Helen G Coleman; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

8.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Authors:  Frederick Arce Vargas; Andrew J S Furness; Isabelle Solomon; Kroopa Joshi; Leila Mekkaoui; Marta H Lesko; Enrique Miranda Rota; Rony Dahan; Andrew Georgiou; Anna Sledzinska; Assma Ben Aissa; Dafne Franz; Mariana Werner Sunderland; Yien Ning Sophia Wong; Jake Y Henry; Tim O'Brien; David Nicol; Ben Challacombe; Stephen A Beers; Samra Turajlic; Martin Gore; James Larkin; Charles Swanton; Kerry A Chester; Martin Pule; Jeffrey V Ravetch; Teresa Marafioti; Karl S Peggs; Sergio A Quezada
Journal:  Immunity       Date:  2017-04-11       Impact factor: 31.745

Review 9.  The roles of regulatory B cells in cancer.

Authors:  Yan He; Hongyan Qian; Yuan Liu; Lihua Duan; Yan Li; Guixiu Shi
Journal:  J Immunol Res       Date:  2014-06-02       Impact factor: 4.818

10.  Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.

Authors:  Monika Bilska; Anna Pawłowska; Ewelina Zakrzewska; Agata Chudzik; Dorota Suszczyk; Marek Gogacz; Iwona Wertel
Journal:  J Oncol       Date:  2020-02-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.